Genomic Landscape of Ceritinib
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Sponsor: Novartis Pharmaceuticals
Terminated
Changes in treatment plans affecting drug therapy choices
Other terminated trials from Novartis Pharmaceuticals
Other Carcinoma, Non-Small-Cell Lung trials with similar outcome
A observational or N/A phase clinical study on Carcinoma, Non-Small-Cell Lung and Non-Small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
▶ Show 4 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Feb 2017 — Mar 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .